+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Xalkori

  • PDF Icon

    Report

  • 19 Pages
  • August 2018
  • Region: Global
  • Citeline
  • ID: 4775211
Drug Overview
Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor (c-Met or hepatocyte growth factor), ROS1, and anaplastic lymphoma kinase (ALK) tyrosine kinases, which are implicated in the progression of several cancers, including non-small cell lung cancer (NSCLC). Gene rearrangements result in fusion proteins with constitutive activation of the ALK kinase domain. In NSCLC, the most commonly identified fusion partner for ALK in these rearrangements is the 5'-end of the echinoderm microtubule-associated protein-like 4 gene (EML4). According to Pfizer, fusion of the EML4 gene to ALK (also known as an EML4-ALK translocation) has been reported in 3–5% of all NSCLC cases.

Table of Contents

OVERVIEW
Drug Overview
Product Profiles
Xalkori : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 89: The authors drug assessment summary for dacomitinib in non-small cell lung cancer
Figure 91: Dacomitinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 91: Ensartinib for non-small cell lung cancer – SWOT analysis
LIST OF TABLES
Table 1: Xalkori drug profile
Table 2: Xalkori pivotal trial data in non-small cell lung cancer
Table 3: Xalkori late-phase trial data in non-small cell lung cancer
Table 4: Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Xalkori patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26